Send to

Choose Destination
Int J Trichology. 2019 Nov-Dec;11(6):241-243. doi: 10.4103/ijt.ijt_92_19.

Therapy-Recalcitrant Folliculitis Decalvans Controlled Successfully with Adalimumab.

Author information

Department of Dermatology, Faculty of Medicine, Al Rass General Hospital, Ministry of Health, Ar Rass, Saudi Arabia.
Department of Dermatology, Head of Hair Disorder Unit, King Fahed Armed Forced Hospital, Jeddah, Saudi Arabia.


Folliculitis decalvans (FD) is a rare idiopathic primary cicatricial alopecia which leads to permanent destruction of hair follicular stem cell. Staphylococcus aureus as well as autoimmunity has been implicated in the pathogenesis. Treatment options include topical antiseptics, topical and systemic corticosteroids, systemic antibiotics, isotretinoin, dapsone, hydroxychloroquine, and immunomodulators. We present the therapy-recalcitrant case of FD which is controlled successfully by subcutaneous injections of Adalimumab (Humira®) with no serious adverse events throughout the treatment.


Adalimumab; dermatology life quality index; folliculitis decalvans; tumor necrosis factor alpha

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd Icon for PubMed Central
Loading ...
Support Center